Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b clinical trial of RSM 01 in infants

Trial Profile

A Phase 1b clinical trial of RSM 01 in infants

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RSM 01 (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions

Most Recent Events

  • 18 Mar 2026 According to SK bioscience media release, company announced that it has entered into a funding agreement with the Research Investment for Global Health Technology Foundation (RIGHT Foundation) to receive financial support for early clinical development of its RSV (respiratory syncytial virus) preventive monoclonal antibody candidate, RSM01.Based on this support, SK bioscience plans to accelerate the Phase 1b clinical trial of RSM01 in infants.
  • 16 Feb 2026 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top